The key question is no longer whether to adopt NAMs, but how to implement them with confidence while continuing to meet evolving regulatory expectations and protecting programme value.

Charlotte Hill PhD, Senior Scientist II, explains how cardiac safety screening programmes often feel a lot like playing a game of Tetris. When timelines align, assays run well, data drops cleanly into place and clients have clear answers, there is a Tetris like satisfaction to it all.

Jacob describes his work at Metrion, the technologies he used and how they complemented his PhD research.

Tom will lead business development activities across the UK and EU, supporting Metrion’s continued growth as a global leader in ion channel drug discovery.

Thank you to our customers for their continued trust, collaboration, and partnership and the Metrion team, whose dedication, expertise, and resilience have made this an exceptional year.

Nicole describes her work at Metrion, the technologies she used and how they complemented her PhD research.

As we approach the close of our 10th anniversary year, we reflect on how far Metrion has come, from its scientific roots to becoming a trusted partner in ion channel drug discovery.

Our campaign launched high-throughput NaV1.9 assays which enable our customers to accelerate discovery of novel, non-opioid pain therapeutics with greater efficiency and confidence.

This nomination recognises the outstanding performance of Metrion’s commercial team during the company’s 10th anniversary year, a period that also presented significant challenges across the global life sciences industry.

Cost-effective expertise during critical phases of research, without sacrificing quality